PMID- 26760924
OWN - NLM
STAT- MEDLINE
DCOM- 20160523
LR  - 20181113
IS  - 1879-0852 (Electronic)
IS  - 0959-8049 (Print)
IS  - 0959-8049 (Linking)
VI  - 53
DP  - 2016 Jan
TI  - Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy 
      in patients with neuroendocrine tumors: a radiographic pattern-based approach.
PG  - 163-70
LID - S0959-8049(15)00929-6 [pii]
LID - 10.1016/j.ejca.2015.10.015 [doi]
AB  - PURPOSE: The purpose of this study was to investigate the incidence of 
      drug-related pneumonitis during mammalian target of rapamycin (mTOR) inhibitor 
      therapy in patients with neuroendocrine tumours (NET) and characterise 
      radiographic patterns of pneumonitis. METHODS: Sixty-six patients (39 males, 27 
      females, age: 22-79 years) with advanced NET treated with mTOR inhibitor, 
      everolimus, were retrospectively studied. Chest computed tomography scans during 
      therapy were reviewed for abnormalities suspicious for drug-related pneumonitis 
      by an independent review of two radiologists. Extent, distributions, and specific 
      findings were evaluated in cases positive for pneumonitis. Radiographic patterns 
      of pneumonitis were classified using the American Thoracic Society/European 
      Respiratory Society classification of interstitial pneumonia. RESULTS: 
      Drug-related pneumonitis was radiographically detected in 14 patients (21%). Time 
      from the initiation of therapy to pneumonitis was within 6 months of therapy in 
      10 patients (71%), while it ranged from 1.0 to 27.7 months. Pneumonitis was more 
      common in patients who had never smoked (p=0.03). Lower lungs were more 
      extensively involved than upper and middle lungs. Peripheral and lower 
      distributions were most common (n=8), followed by peripheral and multifocal 
      distributions (n=3). Ground glass and reticular opacities were present in all 
      cases, with consolidation in eight cases. The radiographic pattern of pneumonitis 
      was classified as cryptogenic organising pneumonia (COP) pattern in eight 
      patients, non-specific interstitial pneumonia (NSIP) pattern in five, and 
      hypersensitivity pneumonitis pattern in one patient. CONCLUSION: Drug-related 
      pneumonitis was noted in 21% of the advanced NET patients treated with 
      everolimus. Radiographic pattern of pneumonitis was most commonly COP pattern, 
      followed by NSIP pattern.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Nishino, Mizuki
AU  - Nishino M
AD  - Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer 
      Institute, 450 Brookline Ave., Boston, MA, 02215, USA. Electronic address: 
      Mizuki_Nishino@DFCI.HARVARD.EDU.
FAU - Brais, Lauren K
AU  - Brais LK
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave., 
      Boston, MA, 02215, USA; Department of Medicine, Brigham and Women's Hospital, 75 
      Francis St., Boston, MA, 02215, USA.
FAU - Brooks, Nichole V
AU  - Brooks NV
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave., 
      Boston, MA, 02215, USA; Department of Medicine, Brigham and Women's Hospital, 75 
      Francis St., Boston, MA, 02215, USA.
FAU - Hatabu, Hiroto
AU  - Hatabu H
AD  - Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer 
      Institute, 450 Brookline Ave., Boston, MA, 02215, USA.
FAU - Kulke, Matthew H
AU  - Kulke MH
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave., 
      Boston, MA, 02215, USA; Department of Medicine, Brigham and Women's Hospital, 75 
      Francis St., Boston, MA, 02215, USA.
FAU - Ramaiya, Nikhil H
AU  - Ramaiya NH
AD  - Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer 
      Institute, 450 Brookline Ave., Boston, MA, 02215, USA.
LA  - eng
GR  - K23 CA157631/CA/NCI NIH HHS/United States
GR  - 5K23CA157631/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20160104
PL  - England
TA  - Eur J Cancer
JT  - European journal of cancer (Oxford, England : 1990)
JID - 9005373
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*adverse effects
MH  - Everolimus/*adverse effects
MH  - Female
MH  - Humans
MH  - Intestinal Neoplasms/diagnostic imaging/drug therapy
MH  - Lung Neoplasms/diagnostic imaging/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Neuroendocrine Tumors/*drug therapy
MH  - Pancreatic Neoplasms/diagnostic imaging/drug therapy
MH  - Pneumonia/*chemically induced/pathology
MH  - Retrospective Studies
MH  - Tomography, X-Ray Computed
MH  - Young Adult
PMC - PMC4724503
MID - NIHMS734613
OTO - NOTNLM
OT  - Computed tomography
OT  - Drug toxicity
OT  - Neuroendocrine tumours
OT  - Pneumonitis
OT  - mTOR inhibitor
EDAT- 2016/01/14 06:00
MHDA- 2016/05/24 06:00
PMCR- 2017/01/04
CRDT- 2016/01/14 06:00
PHST- 2015/10/08 00:00 [received]
PHST- 2015/10/18 00:00 [accepted]
PHST- 2016/01/14 06:00 [entrez]
PHST- 2016/01/14 06:00 [pubmed]
PHST- 2016/05/24 06:00 [medline]
PHST- 2017/01/04 00:00 [pmc-release]
AID - S0959-8049(15)00929-6 [pii]
AID - 10.1016/j.ejca.2015.10.015 [doi]
PST - ppublish
SO  - Eur J Cancer. 2016 Jan;53:163-70. doi: 10.1016/j.ejca.2015.10.015. Epub 2016 Jan 
      4.